SCH 48973: A potent, broad-spectrum, antienterovirus compound

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1220-1225

  Buontempo, Peter J ^a   Cox, Stuart ^a   Wright Minogue, Jacquelyn ^a   DeMartino, Jason L ^a   Skelton, Angela M ^a   Ferrari, Eric ^a   Albin, Randi ^a   Rozhon, Edward J ^a,c   Girijavallabhan, V ^a   Modlin, John F ^b   O'Connell, John F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Shaman Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; SCH 48973; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL SURVIVAL; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; ENTEROVIRUS; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS CAPSID; VIRUS INFECTION;

EID: 8244260089     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1220     Document Type: Article

References (53)

1. Al-Nakib, W., P. G. Higgins, G. I. Barrow, D. A. J. Tyrrell, K. Andries, G. Vanden Bussche, N. Taylor, and P. A. J. Janssen. 1989. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob. Agents Chemother. 33:522-525.
2. Andries, K., B. Dewindt, M. De Brabander, R. Stokborekx, and P. A. J. Janssen. 1988. In vitro activity of R61837, a new rhinovirus compound. Arch. Virol. 101:155-167.
3. Andries, K., B. Dewindt, J. Snoeks, and R. Willebrords. 1989. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization. Virology 106:51-61.
4. Arnold, E. J. Personal communication.
5. Badger, J., I. Minor, M. J. Kremer, M. A. Oliveira, T. J. Smith, J. P. Griffith, D. M. A. Guerin, S. Krishnaswamy, M. Luo, M. G. Rossmann, M. A. McKinlay, G. D. Diana, F. J. Dutko, M. Fancher, R. R. Rueckert, and B. A. Heinz. 1988. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl. Acad. Sci. USA 85:3304-3308.
6. Barrow, G. I., P. G. Higgins, D. A. J. Tyrrell, and K. Andries. 1990. An appraisal of the efficacy of the antiviral R61837 in rhinovirus infections in human volunteers. Antivir. Chem. Chemother. 5:279-283.
7. Bennett, J. P. 1978. Methods in binding studies, p. 57-90. In H. I. Yamamura, S. J. Enna, and M. J. Kuhar (ed.), Neurotransmitter receptor binding. Raven Press, New York, N.Y.
8. Chapman, M. S., I. Minor, M. G. Rossmann, G. D. Diana, and K. Andries. 1991. Human rhinovirus 14 complexed with antiviral compound R 61837. J. Mol. Biol. 217:455-463.
9. Cox, S., P. J. Buontempo, J. Wright-Minogue, J. L. DeMartino, A. M. Skelton, E. Ferrari, J. Schwartz, E. J. Rozhon, C. C. Linn, V. Girijavallabhan, and J. F. O'Connell. 1996. Antipicornavirus activity of SCH 47802 and analogues: in vitro and in vivo studies. Antivir. Res. 32:71-79.
10. Dagan, R., C. B. Hall, K. R. Powell, and M. A. Menegus. 1989. Epidemiology and laboratory diagnosis of infection with viral and bacterial pathogens in infants hospitalized for suspected sepsis. J. Pediatr. 115:351-356.
11. Davies, O. L., and P. L. Goldsmith. 1972. Statistical methods in research and production, p. 317-323. Hasfner Publishing Company, New York, N.Y.
12. Diana, G. D., M. A. McKinlay, C. J. Brisson, E. S. Zalay, J. V. Miralles, and U. J. Salvador. 1985. Isoxazoles with antipicornavirus activity. J. Med. Chem. 28:748-752.
13. Eggers, H. J., M. A. Koch, A. Furst, G. D. Daves, Jr., J. J. Wilczynski, and K. Folkers. 1970. Rhodanine: a selective inhibitor of the multiplication of echovirus 12. Science 167:294-297.
14. Filman, D. J., R. Syed, M. Chow, A. J. Macadam, P. D. Minor, and J. M. Hogle. 1989. Structural factors that control conformational transitions and scrotype specificity in type 3 poliovirus. EMBO J. 8:1557-1579.
15. Fox, M. P., M. J. Otto, and M. A. McKinlay. 1986. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob. Agents Chemother. 30:110-116.
16. Fox, M. P., M. A. McKinlay, G. D. Diana, and F. J. Dutko. 1991. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14. Antimicrob. Agents Chemother. 35:1040-1047.
17. Girijavallabhan, V., A. Ganguly, and R. Versace. September 1995. U.S. patent 5,350,772.
18. Greve, J. M., G. Davis, A. M. Meyer, C. P. Forte, S. C. Yost, C. W. Marlor, M. E. Kamarck, and A. McClelland. 1989. The major human rhinovirus receptor is ICAM-1. Cell 56:839-847.
19. Hayden, F. G., A. Andries, and P. A. J. Janssen. 1992. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 36:727-732.
20. Hierholzer, J. C., K. A. Hilliard, and J. J. Esposito. 1975. Serosurvey for "acute hemorrhagic conjunctivitis" virus (enterovirus 70) antibodies in the southeastern United States, with review of the literature and some epidemiologic implications. Am. J. Epidemiol. 102:533-544.
21. Higgins, P. G., P. J. Scott, P. M. Daniels, and D. R. Gamble. 1974. A comparative study of viruses associated with acute hemorrhagic conjunctivitis. J. Clin. Palhol. 27:292-296.
22. Hogle, J. M., M. Chow, and D. J. Filman. 1985. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358-1365.
23. Ishitsuka, H., C. Ohsawa, T. Ohiwa, I. Umeda, and Y. Suhara. 1982. Antipicornavirus flavone Ro 09-0179. Antimicroh. Agents Chemother. 22:611-616.
24. Jubelt, B., G. Ghislaine, O. Narayan, and R. T. Johnson. 1980. Pathogenesis of human poliovirus infection in mice. 1. Clinical and pathogenesis studies. J. Neuropathol. Exp. Neurol. 39:138-148.
25. Kenny, M. T., J. K. Dulworth, T. M. Bargar, and J. K. Daniel. 1987. Antipicornavirus activity of some diaryl methanes and aralkylamino-pyridines. Antivir. Res. 7:87-97.
26. Kim, S., T. J. Smith, M. S. Chapman, M. G. Rossmann, D. Pevear, F. J. Dutko, J. P. Felock, G. D. Diana, and M. A. McKinlay. 1989 Crystal structure of human rhinovirus serotype 1A (HRV 1A). J. Mol. Biol. 210:91-111.
27. McKinney, R. I., S. L. Katz, and C. M. Wilfert. 1987. Chronic enteroviral meningoencephalitis in agammaglobulin patients. Rev. Infect. Dis 9:334-356.
28. McSharry, J. J., L. A. Caliguiri, and H. J. Eggers. 1979. Inhibition of uncoating of poliovirus by arildone, a new antiviral drug. Virology 97:307-315.
29. Modlin, J. Personal communication.
30. Modlin, J. F. 1990. Coxsackieviruses, echoviruses, and newer enteroviruses, p. 1367-1383. In G. L. Mandell, R. G. Douglas, Jr., and J. E. Bennett (ed.), Principles and practice of infectious disease, 3rd ed. Churchill Livingstone, Inc., New York. N.Y.
31. Mossmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
32. Muckelbvauer, J. K., M. Kremer, I. Minor, G. Diana, F. Dutko, J. Groake, D. C. Pevear, and M. G. Rossmann. 1995. The structure of coxsackievirus B3 at 3.5 Å resolution. Structure 3:653-667.
33. 30a. National Institutes of Health. 1985. Guide for the care and use of laboratory animals. NIH publication 85-23. National Institutes of Health, Bethesda, Md.
34. O'Connell, J. F., R. Albin, D. Blum, P. Grint, and J. Schwartz. 1995. Development of antiviral agents for picornavirus infections, p. 419-434. In H. A. Rotbart (ed.), Human enterovirus infections. ASM Press, Washington, D.C.
35. Oliveira, M. A., R. Zhao, W.-M. Lee, M. J. Kremer, I. Minor, R. R. Rueckert, G. D. Diana, D. C. Pevear, F. J. Dutko, M. A. McKinlay, and M. G. Rossmann. 1993. The structure of human rhinovirus 16. Structure 1:51-68.
36. Otto, M. J., M. P. Fox, M. J. Fancher, M. F. Kuhrt, G. D. Diana, and M. A. McKinlay. 1985. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 27:883-886.
37. Pevear, D. C., M. J. Fancher, P. J. Felock, M. G. Rossmann, M. S. Miller, G. Diana, A. M. Treasurywala, M. A. McKinlay, and F. J. Dutko. 1989. Conformational change in the floor of the human rhinovirus canyon Mocks adsorption to HcLa cell receptors. J. Virol. 63:2002-2007.
38. Rossmann, M. G., E. Arnold, E. A. Erickson, E. A. Frankenberger, J. P. Griffith, H.-J. Hecht, J. E. Johnson, and G. Kamer. 1985. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317:145-153.
39. Rotbart, H. A. 1989. Human enterovirus infections: molecular approaches to diagnosis and pathogenesis, p. 243-264. In B. L. Semler and E. Ehrenfeld (ed.), Molecular aspects of picornavirus infection and detection. American Society for Microbiology, Washington, D.C.
40. Rozhon, E., S. Cox, P. Buontempo, J. O'Connell, W. Slater, J. DeMartino, J. Schwartz, G. Miller, E. Arnold, A. Zhang, C. Morrow, S. Jablonski. P. Pinto, R. Verace, T. Duelfer, and V. Girijavallabhan. 1993. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antivir. Res. 21:15-35.
41. Rozhon, E. J., H. L. Lipton, and F. Brown. 1982. Characterization of Theiler's murine virus RNA. J. Gen. Virol. 61:157-165.
42. Rueckert, R. R., and M. A. Pallansch. 1981. Preparation and characterization of encephalomyocarditis virus. Methods Enzymol. 78:315-325.
43. Rueckert, R. R. 1990. Picornaviridae and their replication, p. 507-548. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
44. Schiff, G. M., J. R. Sherwood, E. C. Young, and L. J. Mason. 1992 Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackievirus A21 infection and illness. Antivir. Res. 17(Suppl. 1):92.
45. Staunton, D. E., V. J. Merluzzi, R. Rothlein, R. Barton, S. D. Marlin, and T. A. Springer. 1989. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 56:849-853.
46. Strikas, R. A., L. J. Anderson, and R. A. Parker. 1986. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States. 1970-1983. J. Infect. Dis. 153:346-351.
47. Tomassini, J. E., D. Graham, C. M. DeWitt, D. W. Lineberger, J. A. Rodkey, and R. J. Colonno. 1989. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA 86:4907-4911.
48. Trousdale, M. D., R. E. Paque, and C. J. Gauntt. 1977. Isolation of coxsackievirus B3 temperature sensitive mutants and their assignment to complementation groups. Biochem. Biophys. Res. Commun. 76:368-375.
49. Turner, R. B., F. J. Dutko, N. H. Golstein, G. Lockwood, and F. G. Hayden. 1993. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob. Agents Chemother. 37:297-300.
50. Woods, M. G., G. D. Diana, M. C. Rogge, M. J. Otto, F. J. Dutko, and M. A. McKinlay. 1989. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 33:2069-2074.
51. Yin-Murphy, M. 1984. Acute hemorrhagic conjunctivitis. Prog. Med. Virol. 29:43-44.
52. Zhang, A., R. G. Nanni, G. F. Arnold, D. A. Oren, T. Li, A. Jacobo-Molina, R. L. Williams, G. Kamer, D. A. Rubenstein, Y. Li, E. Rozhon, S. Cox, P. Buontempo, J. O'Connell, J. Schwartz, G. Miller, C. Nash, B. Bauer, R. Versace, A. Ganguly, V. Girijavullabhan, and E. Arnold. 1991. Structure of a complex of human rhinovirus 14 with a water soluble antiviral compound SCH 38057. J. Mol. Biol. 230:857-867.
53. Zhang, A., R. G. Nanni, D. A. Oren, E. J. Rozhon, and E. Arnold. 1992. Three-dimensional structure-activity relationships tor antiviral agents that interact with picornavirus capsids. Semin. Virol. 3:453-471.